Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia
ConditionPreeclampsia (PE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAin Shams Maternity Hospital
About this trial
The goal of this observational study is to learn about the effects of the different drug regimens of magnesium sulphate in treatment of (severe pre-eclampsia). This condition affects some pregnant women and raises their blood pressure. It may also cause seizures (fits). The medication (magnesium sulphate) helps to prevent seizures. The main question this study aims to answer is:
What are the different regimens of magnesium sulphate that are used to prevent seizures in pregnant women with severe pre-eclampsia?
Participants already have taken the magnesium sulphate as part of their regular medical care for severe pre-eclampsia. Researchers will look into the records of the participants in the past 5 years to collect the data.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All hospital records of patients diagnosed as preeclampsia with severe features planned to receive magnesium sulphate.
Disqualifiers
Records with missing data about the regimen of magnesium sulphate used
Trial population
Hospital records will be reviewed for pregnant women presented to Ain Shams University Maternity Hospital (ASUMH) diagnosed as a case of preeclampsia with criteria of severity: Preeclampsia with severe hypertension that does not respond to treatment or is associated with ongoing or recurring severe headaches, visual scotomata, nausea or vomiting, epigastric pain, oliguria, and severe hypertension, as well as progressive deterioration in laboratory blood tests such as rising creatinine or liver transaminases or falling platelet count, or failure of fetal growth or abnormal doppler findings.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
400 Participants
are grouped into 1 trial groupGroup A: pregnant women with severe preeclampsia
Trial outcomes
Primary outcomes
1
Occurrence of eclamptic fits
Development of generalized tonic clonic convulsions in pregnant women with preeclampsia
Time frame
within 24 hours before or after deliverySecondary outcomes
1
ICU admission
admission to the intensive care unit
Time frame
within 48 hours before or after delivery2
magnesium sulphate toxicity
clinical: defined as a presence of respiratory depression with less than 16 respirations per minute or loss of deep tendon reflexes necessitating cessation of MgSO4 or administration of calcium gluconate and / or biochemical: serum magnesium level \>8.4mg/dl
Time frame
within 48 hours before or after delivery3
primary postpartum hemorrhage
occurrence of complications as primary postpartum hemorrhage (the loss of 500 ml or more of blood from the genital tract within 24 hours of the birth of a baby)
Time frame
within 24 hours after deliverySponsors and contacts
Click on the lead sponsor to view all of their trials.
Ain Shams Maternity Hospital
Lead sponsor
Ain Shams University
Sponsor institution
Source ClinicalTrials.gov